You are here: Industry Insights > Heart failure

News List

Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction worldpharmanews
January 07, 2020
AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failu
Diabetes Mellitus May Increase Risk for Developing Heart Failure drugs
January 03, 2020
Patients with diabetes mellitus have an increased risk for heart failure, even in the absence of diastolic dysfunction ...
Improved Oral Hygiene May Cut Risk for Heart Failure, A-Fib drugs
December 26, 2019
Improved oral hygiene care is associated with a reduced risk for atrial fibrillation and heart failure, according to a study published online in the European Journal of Preventive Cardiology.
Risk Score Developed to Help ID Heart Failure Risk in Leukemia drugs
December 20, 2019
In a study published in the December issue of JACC: CardioOncology, authors investigated the occurrence and developed a risk score to determine the risk for heart failure in patients with ...
Pregnancy-Related Heart Failure Tied to Higher Cancer Risk drugs
December 19, 2019
Patients with peripartum cardiomyopathy (PPCM) are more likely to have cancer before PPCM diagnosis and more likely to develop cancer after PPCM ...
Trastuzumab Tied to Higher Long-Term Risk for Heart Failure drugs
March 21, 2019
Compared with chemotherapy alone, trastuzumab is associated with a twofold increased long-term risk for heart failure in breast cancer survivors, according to a study published in the March 1 issue of JACC: Heart Failure.
Diabetes drug effective against heart failure in wide spectrum of patients worldpharmanews
March 19, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction...
Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure worldpharmanews
February 22, 2019
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure)
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall americanpharmaceuticalreview
January 14, 2019
Aurobindo Pharma is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of .....
Moderate Drinking Not Harmful for Seniors With Heart Failure drugs
January 04, 2019
For older adults with heart failure, limited alcohol consumption after diagnosis is associated with survival benefit versus long-term abstinence, according to a study published online Dec. 28 in JAMA Network Open......

Previous page 1 2 3 4 5 6 7 Next page